吉野孝之
吉野, 孝之
VIAF ID: 252788627 (Personal)
Permalink: http://viaf.org/viaf/252788627
Preferred Forms
- 100 1 _ ‡a 吉野, 孝之
- 100 1 _ ‡a 吉野, 孝之
- 100 0 _ ‡a 吉野孝之
4xx's: Alternate Name Forms (8)
Works
Title | Sources |
---|---|
The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC) | |
A new prognostic and predictive tool for shared decision making in stage III colon cancer | |
O4-3 Utility of an artificial intelligence-curation system, QA Commons, for clinical sequencing: SCRUM-Japan MONSTAR-SCREEN | |
Panitsumumabu no jitsurinshō : Bekutibikkusu o tadashiku tsukaikonasu kotsu | |
[Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. | |
Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. | |
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors | |
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients | |
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer | |
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study) | |
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 | |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial | |
[Predictive biomarkers for anti-EGFR antibodies]. | |
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer | |
Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis. | |
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery | |
Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer | |
A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer | |
PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN | |
Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma | |
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations | |
Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic co | |
The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors | |
Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma | |
Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal A | |
Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al | |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer | |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. | |
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution | |
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma | |
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. | |
SCRUM-Japan genesis virtual sequencing (VSQ) project: A novel algorithm combining deep learning (DL) with pathological diagnostics to enable the prediction of BRAF mutations and microsatellite instability (MSI) in advanced colorectal cancer (CRC) | |
SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors | |
Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. | |
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. | |
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel | |
Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor | |
Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan | |
Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. | |
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial | |
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study | |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab | |
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer | |
Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis | |
Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients | |
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel | |
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer | |
パニツムマブの実臨床 : ベクティビックスを正しく使いこなすコツ | |
大腸癌に対するレゴラフェニブ治療 = Regorafenib treatment for colorectal cancer | |
大腸癌治療におけるセツキシマブのすべて | |
進行・再発大腸癌の分子標的治療 |